Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares
Treatment of influenza with baloxavir is anticipated to offer value for money within Japan's healthcare system, delivering significant clinical benefits both for the general population and for all age and risk groups. Accounting for the treatment's impact on influenza transmission adds another dimension of value and further reinforces the evidence supporting the growing use of baloxavir in Japan.
Authors
- Satoki Fujita (ORCID: https://orcid.org/0000-0002-0107-4402)
- Takahiro Takazono (ORCID: https://orcid.org/0000-0002-0696-5386)
- Mariia Dronova (ORCID: https://orcid.org/0000-0003-1645-5678)
- Anna Tytuła
- Vladislav Berdunov (ORCID: https://orcid.org/0000-0002-5743-2184)
- Naoya Itsumura (ORCID: https://orcid.org/0000-0002-4183-0604)
- S. Eymere (ORCID: https://orcid.org/0000-0001-8074-5480)
- Hiroshi Mukae (ORCID: https://orcid.org/0000-0002-1429-5706)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Naoki Hosogaya (ORCID: https://orcid.org/0000-0002-3229-2277)
- Shogo Miyazawa
Institutions
- University of Agriculture in Krakow (PL)
- Shionogi (Japan) (JP)
- Hôpital Purpan (FR)
- Nagasaki University Hospital (JP)
- Nagasaki University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1007/s40121-025-01203-5
- Citations
- 2
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Shionogi